Please confirm topic selection

Are you sure you want to trigger topic in your Anconeus AI algorithm?

Please confirm action

You are done for today with this topic.

Would you like to start learning session with this topic items scheduled for future?

Updated: Nov 29 2021

Anti-Mycobacterials

  • Introduction
    • Drugs
      • rifamycins
      • isoniazid
      • pyrazinamide
      • ethambutol
      • dapsone
      • clofazimine
      • streptomycin
    • Clinical use
      • Classic Treatment Paradigm for Mycobacteria
      • Organism
      • Prophylaxis
      • Treatment
      • Mycobacterium tuberculosis
      • Isoniazid
      • Active infection: RIPE therapy
      • Rifampin
      • Isoniazid
      • Pyrazinamide
      • Ethambutol
      • Latent infection:
      • isoniazid x 9 months
      • Mycobacterium avium-intracellulare
      • Azithromycin
      •  Rifabutin
      • Azithromycin + ethambutol
      •  Can also add rifabutin or ciprofloxacin
      • Mycobacterium leprae
      • Tuberculoid: dapsone + rifampin
      •  Lepromatous: dapsone + rifampin + clofazimine
    • Anti-Mycobacterial Medications
      DrugMechanism of Action
      Adverse Effects
      Notes

      Rifamycins (rifampin and rifabutin)

      • Inhibits DNA-dependent RNA polymerase
      • Hepatotoxicity
      • Red or orange body fluids
      • CYP450 inducer
      • Rifabutin has less CYP450 effect, thus favored for HIV patients
      • Mutations occur due to decreased binding to RNA polymerase
      • Resistance occurs rapidly if used as monotherapy
      Isoniazid
      • Inhibits synthesis of mycolic acids
      • Hepatotoxicity
      • Inhibits CYP450
      • Drug-induced systemic lupus erythematosus
      • Vitamin B6 deficiency
        • peripheral neuropathy
        • sideroblastic anemia
        • co-administer with pyridoxine (B6) to reduce side effects
      • May be used as monotherapy for prophylaxis and latent TB
      • Mutations occur due to underexpression of enzyme required to convert drug into active metabolite
      Pyrazinamide
      • Unknown but may work through host phagolysosomes
      • Hepatotoxicity
      • Hyperuricemia
      -
      Ethambutol
      • Inhibits arabinosyltransferase and disrupts cell wall
      • Optic neuropathy
        • red-green color blindness
      -
      Dapsone
      • Inhibits dihydropteroate synthesis (anti-folate)
      • Methemoglobinemia
      • Hemolysis (G6PD deficiency patients)
      -
      Clofazimine
      • Disrupts DNA
      • Gastrointestinal upset
      • Dry skin
      • Pink/brown skin and body fluid dyspigmentation
      -
      Streptomycin
      • Interacts with 30S ribosomal subunit
      • Tinnitus
      • Vertigo
      • Ataxia
      • Renal toxicity
      • Second-line treatment forM. tuberculosis
      • Anti-Mycobacterial Medications
      • Drug
      • Mechanism of Action
      • Adverse Effects
      • Notes
Card
1 of 0
Private Note

Attach Treatment Poll
Treatment poll is required to gain more useful feedback from members.
Please enter Question Text
Please enter at least 2 unique options
Please enter at least 2 unique options
Please enter at least 2 unique options